KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Long-Term Debt Repayments (2016 - 2025)

Pfizer (PFE) has disclosed Long-Term Debt Repayments for 17 consecutive years, with $3.0 billion as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments changed N/A to $3.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $6.8 billion for FY2025, 200.31% up from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was $3.0 billion at Pfizer, down from $3.8 billion in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $3.8 billion in Q2 2025, with the low at $269.0 million in Q2 2023.
  • Average Long-Term Debt Repayments over 5 years is $1.6 billion, with a median of $1.3 billion recorded in 2023.
  • The sharpest move saw Long-Term Debt Repayments plummeted 83.28% in 2023, then surged 364.68% in 2024.
  • Over 5 years, Long-Term Debt Repayments stood at $1.0 billion in 2021, then skyrocketed by 60.74% to $1.6 billion in 2022, then decreased by 19.2% to $1.3 billion in 2023, then skyrocketed by 73.08% to $2.2 billion in 2024, then surged by 33.64% to $3.0 billion in 2025.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $3.0 billion, $3.8 billion, and $2.2 billion for Q4 2025, Q2 2025, and Q3 2024 respectively.